Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a report issued on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on ALIM. Maxim Group reiterated a hold rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Alliance Global Partners restated a neutral rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, HC Wainwright downgraded Alimera Sciences from a buy rating to a neutral rating and set a $6.00 target price on the stock. in a research note on Tuesday, June 25th.

Alimera Sciences Stock Performance

Shares of ALIM stock opened at $5.55 on Friday. The stock’s 50-day moving average is $5.56 and its two-hundred day moving average is $4.31. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.62 and a current ratio of 2.79. Alimera Sciences has a 1 year low of $2.61 and a 1 year high of $5.65. The firm has a market cap of $301.81 million, a price-to-earnings ratio of -3.54 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. Analysts predict that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Alimera Sciences

A number of hedge funds have recently added to or reduced their stakes in ALIM. Renaissance Technologies LLC boosted its stake in shares of Alimera Sciences by 3.9% in the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock valued at $1,010,000 after buying an additional 6,900 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Alimera Sciences during the 2nd quarter worth $113,000. Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences during the 1st quarter worth $83,000. Hillsdale Investment Management Inc. acquired a new position in shares of Alimera Sciences during the 1st quarter worth $169,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Alimera Sciences in the 2nd quarter valued at about $344,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).